https://www.selleckchem.com/pr....oducts/phosphoenolpy
to ACHBLF. The sensitivity and specificity of UBE2Q1 promoter methylation status combined with the model for end-stage liver disease score for early diagnosis of ACHBLF were 92.9% and 75.0%, respectively. The area under the receiver-operating characteristic curve was 0.895.The hypomethylation of UBE2Q1 promoter is associated with severity of Pre-ACHBLF, which could serve as a potential prognostic biomarker for pre-ACHBLF. Coronavirus disease 2019 (COVID-19) is an emerging and rapidly evolving disease,
Like
Comment
Share
